Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Risk to benefit ratio is not acceptable

Conditions

Castration Levels of Testosterone
Hormone-Resistant Prostate Cancer
Metastatic Prostate Carcinoma in the Soft Tissue
Prostate Carcinoma Metastatic in the Bone
PSA Progression
Stage IV Prostate Adenocarcinoma AJCC v7

Interventions

DRUG: Selinexor

Sponsor

University of California, San Francisco

Collaborators

[object Object]